IUBio Biosequences .. Software .. Molbio soft .. Network News .. FTP

Safety of Varivax

Richard Spaete spaete at biomail.aviron.com
Thu Apr 27 15:51:58 EST 1995


                       Subject:                               Time:9:53 AM
  OFFICE MEMO          Safety of Varivax                      Date:4/27/95
     More than 11,000 adults, adolescents and children participated in Merck's Varivax
trials over a ten year period.  Adverse reactions were mild.  Eight cases of
zoster were reported in children (44,994 person-years of follow-up).  These
project a calculated incidence of 18 cases per 100,000 person years.  One case
of zoster was reported in the adolescent/adult group (7,826 person-years of follow-up).
 All nine cases were mild and without sequelae (SCRIP No 2011 march 28, 1995, p.
20).
     The Japanese experience has been similar.  In a twenty year follow-up of a
small number of patients (n=96), no cases of zoster were reported and all showed
positive skin reaction.  Therefore, boosters may not be required.   The sum of
their data indicates long-lasting protective immunity (reported at the 19th
Intl. Herpesvirus Workshop in Vancouver B.C. 30 jul-5 aug, 1994).  
     This vaccine has been approved in Japan and several European countries for
years.  By all measures it is safe and effective (and cost-effective to use that
buzz word).   You virologists in the group should be leading opinion toward
widespread useage of this vaccine. 
     




More information about the Virology mailing list

Send comments to us at biosci-help [At] net.bio.net